Novartis Pharmaceuticals

This early-phase study tested a new drug called FAZ053, alone or with another drug (PDR001), in 154 adults with advanced solid tumors (including triple-negative breast cancer and rare sarcomas). The main goal was to check safety and find the right dose. The drug works by helping …

This study checked the long-term safety of ligelizumab, an investigational drug for food allergy. It included 163 people who had already finished a phase 3 study on ligelizumab. The main goal was to track side effects over three years.

This study tested a new, easy-to-take malaria tablet for babies weighing less than 5 kg who had uncomplicated malaria. The goal was to see how the medicine worked in the body and if it was safe and effective. The trial was stopped early and included 28 infants and newborns.

This study tested whether adding alpelisib to standard chemotherapy (nab-paclitaxel) could help people with advanced triple negative breast cancer that has specific genetic changes (PIK3CA mutation or PTEN loss). The trial enrolled 137 participants but was terminated early, meani…

This study tested whether adding the experimental drugs NIS793 (with or without spartalizumab) to standard chemotherapy could help people with metastatic pancreatic cancer that had not been treated before. The trial was stopped early, so results are limited. It involved 164 adult…

This study tested an experimental drug called TIN816 in adults at risk for acute kidney injury after heart surgery. The goal was to see if the drug could prevent or reduce kidney damage compared to a placebo. The trial was stopped early, and results are being analyzed to determin…

This early-phase study tested different drug combinations in 122 adults with advanced or metastatic BRAF V600 colorectal cancer. The main goal was to understand safety, side effects, and find the best doses for future studies. The trial was terminated, but the results help guide …

This early-stage study tested a new drug called DFF332 in people with advanced clear cell kidney cancer. The drug works by blocking a protein (HIF2α) that helps some cancers grow. Researchers gave DFF332 alone or with other drugs to see if it was safe and could shrink tumors. The…

This study tested whether adding the experimental drug MBG453 to standard chemotherapy (azacitidine) could help adults with high-risk myelodysplastic syndrome (MDS) or a related leukemia (CMML-2) live longer. About 530 participants were planned, but the trial was stopped early. T…

This study tested a new drug called JBH492 in 25 people with relapsed or hard-to-treat chronic lymphocytic leukemia (CLL) or non-Hodgkin's lymphoma (NHL). The main goal was to check safety and find the right dose. The trial was stopped early, so results are limited.

This early-stage study tested two new drug combinations in 52 adults with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS), types of blood and bone marrow cancer. The goal was to find safe doses and understand side effects. The study was terminated early, …

This early-stage study tested an experimental drug called VAY736, alone or with other cancer drugs, in 18 adults with certain types of Non-Hodgkin lymphoma that had come back or not responded to standard treatments. The main goals were to check the drug's safety and how the body …

This early-stage study tested a new radioactive drug called 177Lu-FF58 in 24 people with advanced pancreatic, stomach, or brain cancers that had spread or come back. The main goal was to check the drug's safety and find the right dose. The study was stopped early, so results are …

This study tested a new drug called sabatolimab added to standard chemotherapy for people with a bone marrow disorder called myelodysplastic syndrome (MDS) at intermediate to very high risk. The main goal was to check safety, and the study also looked at how many patients achieve…

This study tested whether adding an immunotherapy drug (PDR001) to two standard targeted drugs (dabrafenib and trametinib) could help people with advanced melanoma that has a specific BRAF gene change. The trial planned to include about 568 people but was stopped early. The main …

This early-phase study tested a new drug called WVT078, alone or with another drug (WHG626), in people with multiple myeloma that returned or didn't respond to prior treatments. The main goal was to find a safe dose and check for side effects. The study was stopped early, so resu…

This study tested a new drug combination (ribociclib plus topotecan and temozolomide) in children and young adults with neuroblastoma or other solid tumors that had come back or not responded to treatment. The goal was to find a safe dose and see if it could help control the canc…

This study looked at the long-term safety of an experimental drug called LTP001 for people with pulmonary arterial hypertension (PAH), a serious lung condition that makes it hard for the heart to pump blood. It was an extension study for people who had already completed an earlie…

This study tested a drug called secukinumab in adults with active, moderate-to-severe thyroid eye disease, a rare autoimmune condition that causes eye bulging and inflammation. The trial was stopped early, so only limited data were collected. The goal was to see if the drug could…

This early-phase study tested a new drug called QEQ278 in 30 adults with advanced lung, kidney, esophageal, or head and neck cancers that had stopped responding to standard treatments. The main goals were to check safety and find the right dose. The trial was terminated early, so…

This early-stage study tested a gene-edited stem cell treatment (OTQ923) in 4 people with severe sickle cell disease. The goal was to boost fetal hemoglobin to reduce painful crises and other complications. The trial was terminated early, so full results are limited, but it aimed…

This study tested a medicine called ensovibep in adults with mild-to-moderate COVID-19 who were not hospitalized. The goal was to see if it could lower the amount of virus in the body and reduce the need for hospital or emergency care. The trial was stopped early, but the results…

This early-stage study tested a new drug called MGY825 in 41 adults with advanced non-small cell lung cancer that had certain genetic changes. The main goal was to check the drug's safety and find the right dose. The study was stopped early, so results are limited.

This study aimed to see if the drug capmatinib, given before and after surgery, could improve outcomes for people with early-stage non-small cell lung cancer that has a specific genetic change (MET mutation). Only 4 people enrolled, and the trial was stopped early, so we don't ha…

This study tested whether combining two drugs, alpelisib and olaparib, works better than standard chemotherapy for people with a certain type of advanced ovarian cancer that no longer responds to platinum-based treatments. Participants had high-grade serous ovarian cancer without…

This study tested a new drug called sabatolimab combined with two standard treatments (azacitidine and venetoclax) in 20 adults with high or very high risk myelodysplastic syndrome (MDS) who could not have intensive chemotherapy or a stem cell transplant. The goal was to see if t…

This early-stage study tested an experimental oral drug called TNO155 in 227 adults with advanced solid tumors (like lung, skin, or esophageal cancer) that had stopped responding to standard treatments. The main goal was to find safe doses and understand side effects, both when g…

This study tested two experimental drugs, VOB560 and MIK665, given together to people with certain blood cancers (non-Hodgkin lymphoma, acute myeloid leukemia, or multiple myeloma) that had come back or stopped responding to treatment. The main goals were to find safe doses and s…

This early-phase study aimed to find safe doses of drug combinations for adults with lower-risk myelodysplastic syndrome (MDS), a blood disorder. Researchers planned to enroll 33 participants to check side effects and how well the drugs were tolerated. The study was terminated ea…

This study tested an experimental drug called LNA043, given as a shot into the knee, to see if it could slow down cartilage loss and reduce pain in people with knee osteoarthritis. The trial planned to enroll 576 adults aged 40 to 75 with knee osteoarthritis. The study was termin…

This study tested a new medicine called XXB750 in 136 people with heart failure and reduced heart pumping ability. The goal was to see if the drug could lower a key stress marker in the blood and improve symptoms. The trial was stopped early, but the results help researchers unde…

This study tested whether adding an extra drug (canakinumab) to standard immunotherapy plus chemotherapy could help people with advanced non-small cell lung cancer live longer or slow their cancer. The trial included 673 adults who had not received prior treatment. Unfortunately,…

This study tested new single treatments for idiopathic pulmonary fibrosis (IPF), a lung disease that causes scarring and breathing problems. It included 46 adults aged 40 and older with mild to moderate IPF. The study was stopped early, so results are limited.

This early-phase study tested a new type of immunotherapy called CAR-T cells, which are the patient's own immune cells modified to attack a protein called BCMA found on myeloma cells. The trial included adults with multiple myeloma that had not responded to at least two prior tre…

This early-stage trial tested a new drug (TNO155) combined with either spartalizumab or ribociclib in adults with advanced solid tumors like lung, head and neck, and colorectal cancers. The main goal was to check safety and find the right dose. The study was terminated, so result…

This study followed 6 adults with paroxysmal nocturnal hemoglobinuria (PNH) who were already taking iptacopan as part of their routine care in Russia. The goal was to see if the drug helped raise hemoglobin levels and reduce the need for blood transfusions over 6 to 12 months. Th…

This study tested whether adding an experimental drug called MBG453 to standard chemotherapy (azacitidine or decitabine) could improve outcomes for people with high-risk myelodysplastic syndrome (MDS), a type of blood cancer. The trial included 127 adults who were not eligible fo…

This study tested an experimental drug called LTP001 in 47 people with pulmonary arterial hypertension (PAH), a condition where high blood pressure damages the arteries in the lungs. The goal was to see if the drug could improve blood flow and exercise ability. The study was stop…

This study tested a new treatment called PHE885 for adults with multiple myeloma that had come back or stopped responding to at least three prior treatments. The therapy uses a patient's own immune cells, modified to attack cancer cells. The study aimed to see how many patients' …

This study tested a new drug (MBG453) combined with two other medicines (azacitidine and venetoclax) in 90 adults with acute myeloid leukemia who were not healthy enough for standard chemotherapy. The goal was to see if the combination could safely help more patients achieve comp…

This study tested an experimental drug called iptacopan in people with two rare blood disorders: immune thrombocytopenia (ITP) and cold agglutinin disease (CAD). The goal was to see if the drug could improve platelet counts in ITP or hemoglobin levels in CAD. The trial was termin…

This study tested an experimental drug called QBW251 in 42 adults with bronchiectasis, a lung condition causing mucus buildup and infections. The goal was to see if the drug could safely reduce bacteria in the lungs and improve symptoms. However, the trial was terminated early, s…

This study tested a drug called sabatolimab in 24 adults and teens with acute myeloid leukemia who still had small amounts of cancer cells after a stem cell transplant. The goal was to see if sabatolimab, alone or with another drug, could prevent the leukemia from coming back wit…

This study tested a new imaging agent called 68Ga-FF58 in 14 adults with certain advanced solid tumors, including glioblastoma and pancreatic cancer. The goal was to see how well it shows up on PET/CT scans and to check its safety. The study was stopped early, so results are limi…

This study tested whether secukinumab, an injected drug, could reduce pain and improve function in adults with moderate to severe rotator cuff tendinopathy (shoulder tendon pain). About 60 people were planned to receive either the drug or a placebo for 24 weeks. The trial was ter…

This study tested whether secukinumab, an injected drug, could reduce pain and improve shoulder function in adults with moderate to severe rotator cuff tendinopathy (a common cause of shoulder pain). Participants received either the drug or a placebo, plus standard care, for 24 w…

This study looked at how a new chewable asthma tablet called fevipiprant works in children aged 6 to 12. The goal was to find the right dose and check for side effects. Only 11 children took part, and the study was stopped early, so results are limited.

This study tested two drugs, canakinumab and LNA043, injected into the knee to see if they could ease pain and protect cartilage in people with knee osteoarthritis. It included 23 adults with moderate to severe knee pain. The study was terminated early, so results are limited.

This study aimed to see if anti-inflammatory drugs could help people with early Alzheimer's disease or mild cognitive impairment. It included 34 participants and was stopped early, so only one drug was tested. The main goal was to measure changes in thinking and memory, but the e…

This study tested an experimental drug called QUC398 in 101 people with painful knee osteoarthritis. The goal was to see if it could reduce knee pain and protect knee cartilage. The trial was stopped early, and results are not yet available.

This study followed 37 adults with migraine who had just started taking erenumab. Over 12 weeks, researchers measured how satisfied patients were with the treatment using a questionnaire. The goal was to see if erenumab improved their experience and symptom control in everyday li…

This study aimed to track side effects, especially high blood sugar, in people with a certain type of advanced breast cancer taking alpelisib plus fulvestrant. It was designed to observe real-world use, not test if the treatment works. Only 4 people enrolled before the study was …

This study looked at whether two simple blood test results—hemoglobin and red blood cell distribution width—can predict if a person with polycythemia vera will stop responding to the drug hydroxyurea. Researchers used a computer model to identify these markers and then tested the…

This study looked at a drug called BLZ945 in people with ALS, a nerve disease that weakens muscles. The goal was to check safety and see if the drug changes brain inflammation using special PET scans. About 28 adults with ALS were planned to join, but the study was stopped early.